3. Anemia Therapy I: Erythropoiesis-Stimulating Agents

  1. Petra Seeber MD1 and
  2. Aryeh Shander MD, FCCM, FCCP2,3

Published Online: 4 JUL 2012

DOI: 10.1002/9781118338070.ch3

Basics of Blood Management, Second edition

Basics of Blood Management, Second edition

How to Cite

Seeber, P. and Shander, A. (2012) Anemia Therapy I: Erythropoiesis-Stimulating Agents, in Basics of Blood Management, Second edition, Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781118338070.ch3

Author Information

  1. 1

    Institute for Blood Management, Gotha, Germany

  2. 2

    Critical Care Medicine and Hyperbaric Medicine, Englewood Hospital and Medical Center, Englewood, NJ, USA

  3. 3

    Mount Sinai School of Medicine, Mount Sinai Hospital, New York, NY, USA

Publication History

  1. Published Online: 4 JUL 2012
  2. Published Print: 24 AUG 2012

ISBN Information

Print ISBN: 9780470670705

Online ISBN: 9781118338070



  • Erythropoietin;
  • Erythropoietin hyporesponsiveness;
  • Malignancy;
  • Adjuvant therapy;
  • Darbepoetin;
  • CERA;
  • Hematide;
  • Anabolic steroids;
  • Prolactin;
  • Melatonin


Erythropoiesis-stimulating agents are one of the three cornerstones for anemia therapy. When administered judiciously, they not only increase red cell mass, but can also improve outcome. However, if used unrestrictedly, they may harm patients, e.g., by modulating the patient's risk for thromboembolic events and promotion of cancer growth. This chapter explains the use of generic recombinant erythropoietin and how practically to overcome obstacles to successful erythropoietin therapy such as erythropoietin resistance. It also describes other erythropoiesis-stimulating agents, such as darbepoetin, CERA, hematide or anabolic steroids, and their potential.